Document:

EX-10.14

 Exhibit 10.14 

CONSULTING AGREEMENT 
 THIS CONSULTING
AGREEMENT (the “Agreement”), is made as of December 17, 2018 (the “Effective Date”) by and between AVROBIO, Inc., a Delaware corporation, with an office at One Kendall Square, Building 300, Suite
201, Cambridge, MA 02139 (“AVROBIO”), and BIVO (CVR no. 39384027), with its office at Soebrinken 2, 2840 Holte, Denmark (together with Birgitte Volck, MD, “Consultant”). For the avoidance of doubt,
Consultant’s obligations pursuant to this Agreement regarding nonsolicitation, work product, and confidentiality are also personal to Volck in her individual capacity. AVROBIO desires to have the benefit of Consultant’s knowledge, skill
and experience, and Consultant desires to provide services to AVROBIO, all as provided in this Agreement. 
  

	1.	 Services. AVROBIO retains Consultant, and Consultant agrees to provide, consulting and
advisory services to AVROBIO as AVROBIO may from time to time reasonably request and as further specified in Exhibit A (the “Consulting Services”). Consultant acknowledges and agrees that AVROBIO is entering into this
Agreement to retain Volck to perform the Consulting Services personally. AVROBIO has determined that Volck is exceptionally qualified to perform them by virtue of her knowledge, skill, and experience. Therefore, Volck shall not delegate the
performance of the Consulting Services to other individuals without the written consent of AVROBIO. Any changes to the Consulting Services (and any related compensation adjustments) must be agreed to in writing between Consultant and AVROBIO prior
to implementation of the changes. 

  

	2.	 Compensation. As full consideration for Consulting Services provided under this Agreement,
AVROBIO agrees to pay Consultant and reimburse expenses as described in Exhibit A. 

  

	3.	 Performance. Consultant agrees to provide the Consulting Services to AVROBIO in accordance with
all applicable laws and regulations and the highest professional standards. Consultant represents and covenants that Consultant has not been, and is not under consideration to be (a) debarred from providing services pursuant to Section 306
of the United States Federal Food Drug and Cosmetic Act, 21 U.S.C. § 335a or similar provisions in other jurisdictions; (b) excluded, debarred or suspended from, or otherwise ineligible to participate in, any federal or state health care
program or federal procurement or non-procurement programs (as that term is defined in 42 U.S.C. §1320a-7b(f) or similar provisions in other jurisdictions); (c)
disqualified by any government or regulatory agencies from performing specific services, and is not subject to a pending disqualification proceeding; or (d) convicted of a criminal offense related to the provision of health care items or
services, or under investigation or subject to any such action that is pending. 

  

	4.	 Compliance with Obligations to Third Parties. Consultant represents and covenants to AVROBIO that
the terms of this Agreement and Consultant’s performance of Consulting Services do not and will not conflict with any of Consultant’s obligations to any third parties. Consultant agrees not to use any trade secrets or other confidential
information of any other person, firm, corporation, institution or other third party in connection with any of the Consulting Services. Consultant agrees not to make any use of any funds, space, personnel, facilities, equipment or other resources of
a third party in performing the Consulting Services, nor take any other action that would result in a third party, including without limitation, an employer of Consultant, asserting ownership of, or other rights in, any Work Product (defined in
Section 6), unless agreed upon in writing in advance by AVROBIO. Consultant represents and warrants that all employees or representatives, if any, performing Consulting Services on behalf of Consultant hereunder are bound by written agreements
requiring them to comply with Consultant’s obligations hereunder. 

  
 Page 1 of 9 

-CONFIDENTIAL- 

	5.	 Exclusivity; Nonsolicitation. 

 

	 	(a)	 During the Term, and only with AVROBIO’s prior written approval, Consultant may accept and perform
engagements for other persons, firms or companies which do not conflict with or materially impinge upon Consultant’s ability to provide the Consulting Services, provided that Consultant may not in any circumstances accept any employment or
engagement with any person, firm or company for the provision of work or services that are competitive with AVROBIO. 

  

	 	(b)	 During the Term, Consultant shall not (i) solicit, encourage, or take any other action which is intended
to induce any director or employee of, or consultant or collaborator to, AVROBIO to terminate his/her employment or relationship with AVROBIO in order to become employed by or otherwise perform services for any other party, or (ii) solicit,
endeavor to entice away from AVROBIO or otherwise interfere with the relationship of AVROBIO with any third party who is, or was within the then-most recent twelve (12) month period, an AVROBIO client, collaborator or customer.

  

	6.	 Work Product. Consultant will promptly and fully disclose in confidence to AVROBIO all
inventions, discoveries, improvements, ideas, concepts, designs, processes, formulations, products, computer programs, works of authorship, databases, mask works, trade secrets, know-how, information, data,
documentation, reports, research, creations and other products arising from or made in the performance of (solely or jointly with others) the Consulting Services (whether or not patentable or subject to copyright or trade secret protection)
(collectively, and including any memorialization thereof by electronic or manual storage, transcription, or recording, and any display, performance or modification thereof or derivative work based thereon, the “Work Product”).
Consultant assigns and agrees to assign to AVROBIO all rights in the United States and throughout the world to Work Product. Consultant will keep and maintain adequate and current written records of all Work Product, and such records will be
available to and remain the sole property of AVROBIO at all times. For purposes of the copyright laws of the United States, Work Product will constitute “works made for hire,” except to the extent such Work Product cannot by law be
“works made for hire”. Consultant represents and covenants that Consultant has and will have the right to transfer and assign to AVROBIO ownership of all Work Product. Consultant will execute all documents, and take any and all actions
needed, all without further consideration, in order to confirm AVROBIO’s rights as outlined above. In the event that Consultant should fail or refuse to execute such documents within a reasonable time, Consultant appoints AVROBIO as attorney to
execute and deliver any such documents on Consultant’s behalf. If Consultant incorporates into any Work Product any information, software, materials or other technology owned by Consultant or in which Consultant has any interest, Consultant
hereby grants, and to the extent any such grant cannot be made at the present, Consultant agrees to grant to AVROBIO a non-exclusive, royalty-free, irrevocable, perpetual, transferable, worldwide license, with
the right to sublicense through multiple tiers, under all such intellectual property rights, to make, use, sell, offer for sale, import, modify, reproduce, create derivative works based upon, distribute, perform, display or otherwise exploit, such
information, software, materials or other technology, in whole or in part, as reasonably required in connection with AVROBIO’s use or exploitation of Work Product or as otherwise reasonably necessary to obtain the benefit of the Consulting
Services. 

  

	7.	 Confidentiality. “Confidential Information” means (a) any scientific,
technical, business or financial information or trade secrets in whatever form (written, oral or visual) that is furnished or made available to Consultant by or on behalf of AVROBIO, (b) all information contained in or comprised of AVROBIO
Materials (defined in Section 8); and (c) all Work Product. Confidential Information is, and will remain, the sole property of AVROBIO. During the Term (as defined in Section 10) and for a period of ten (10) years thereafter (the
“Confidentiality Period”), Consultant agrees to (i) hold in confidence all Confidential Information, and not disclose Confidential Information without the prior written consent of AVROBIO; (ii) use Confidential Information
solely in connection with the Consulting Services; (iii) treat Confidential Information with no less than a reasonable degree of care; (iv) reproduce Confidential Information solely to the extent necessary to provide the Consulting
Services, with all such reproductions being considered Confidential Information; and (v) notify AVROBIO of any unauthorized disclosure of Confidential Information promptly upon becoming aware of such disclosure. Consultant understands that
AVROBIO may from time to time have in its possession certain proprietary or confidential materials and information 

  
 Page 2 of 9 

-CONFIDENTIAL- 

	 	
(including product development plans and specifications) of third parties and which AVROBIO has agreed to keep confidential. Consultant agrees that all such material and information shall be
deemed Materials and Confidential Information, respectively, for purposes of this Agreement. Notwithstanding the foregoing, the non-disclosure and non-use obligations
imposed by this Agreement with respect to any Confidential Information in the form of plasmid maps, plasmid sequences, vector maps, vector sequences and/or any AVROBIO Materials provided hereunder and/or any sequencing information obtained from such
AVROBIO Materials (e.g., regarding plasmids, vectors, or transduced cells) or trade secrets, the Confidentiality Period shall extend in perpetuity unless and until such Confidential Information becomes subject to an exception set forth below.
Consultant’s obligations of non-disclosure and non-use under this Agreement will not apply to any portion of Confidential Information that Consultant can
demonstrate, by competent proof: 

  

	 	(a)	 is generally known to the public at the time of disclosure or becomes generally known through no wrongful act
on the part of Consultant; 

  

	 	(b)	 is in Consultant’s possession at the time of disclosure other than as a result of Consultant’s breach
of any legal obligation; 

  

	 	(c)	 becomes known to Consultant on a non-confidential basis through
disclosure by sources other than AVROBIO having the legal right to disclose such Confidential Information; or 

  

	 	(d)	 is independently developed by Consultant without reference to or reliance upon Confidential Information.

 Notwithstanding any other provision hereof, it shall not be a violation of this Agreement for Consultant to disclose
Confidential Information to the extent such disclosure is required by a governmental authority or by order of a court of competent jurisdiction; provided that in such event, Consultant will give AVROBIO prompt written notice thereof and Consultant
will take all reasonable and lawful actions to avoid or minimize the degree of such disclosure. Consultant will cooperate reasonably with AVROBIO in any efforts to seek a protective order. 

Consultant acknowledges receipt of the following notice under 18 U.S.C § 1833(b)(1): “An individual shall not be held criminally or
civilly liable under any Federal or State trade secret law for the disclosure of a trade secret that (A) is made (i) in confidence to a Federal, State, or local government official, either directly or indirectly, or to an attorney; and
(ii) solely for the purpose of reporting or investigating a suspected violation of law; or (B) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.” 

 

	8.	 AVROBIO Materials. All documents, data, records, materials, compounds, apparatus,
equipment and other physical property furnished or made available by or on behalf of AVROBIO to Consultant in connection with this Agreement and all materials derived therefrom, and all Work Product to the extent such Work Product constitutes
tangible materials (“AVROBIO Materials”) are and will remain the sole property of AVROBIO. Consultant will use AVROBIO Materials only as necessary to perform the Consulting Services and will not transfer or make available to any
third party the AVROBIO Materials without the express prior written consent of AVROBIO. Consultant shall not, nor allow or encourage any third party to, manufacture or analyze or otherwise “reverse engineer” any AVROBIO Materials, and
Consultant shall comply with all laws and regulations regarding the transportation, use and disposal of AVROBIO Materials. Consultant will return to AVROBIO any and all AVROBIO Materials upon request. 

 

	9.	 Publication; Publicity. Consultant may not publish or refer to Work Product, in whole or in part,
without the prior express written consent of AVROBIO. Consultant will not use the name, logo, trade name, service mark, or trademark, or any simulation, abbreviation, or adaptation of same, or the name of AVROBIO or any of its affiliates for
publicity, promotion, or other uses without AVROBIO’s prior written consent. 

  
 Page 3 of 9 

-CONFIDENTIAL- 

	10.	 Expiration/Termination. The term of this Agreement (the “Term”) will commence on
the Effective Date and expire on the date of the earliest to occur of the following: 

  

	 	(i)	 when the condition set forth in Section 21 of the Employment Agreement attached hereto as Exhibit B
is satisfied, as determined by AVROBIO in its reasonable discretion, in which case the Employment Agreement shall become effective in accordance with its terms and govern Volck’s continuing relationship with AVROBIO; 

 

	 	(ii)	 AVROBIO’s immediate termination of this Agreement upon notice to Consultant of an unsatisfactory
background check; 

  

	 	(iii)	 AVROBIO’s termination of this Agreement at any time with or without cause upon not less than five
(5) days’ prior written notice to Consultant; 

  

	 	(iv)	 Consultant’s termination of this Agreement at any time with or without cause upon not less than five
(5) days’ prior written notice to AVROBIO; or 

  

	 	(v)	 the one year anniversary of the Effective Date. 

Any expiration or termination of this Agreement shall be without prejudice to any obligation of either party that has accrued prior to the
effective date of expiration or termination. Upon expiration or termination of this Agreement, neither Consultant nor AVROBIO will have any further obligations under this Agreement, except that (a) Consultant will terminate all Consulting
Services in progress in an orderly manner as soon as practicable and in accordance with a schedule agreed to by AVROBIO, unless AVROBIO specifies in the notice of termination that Consulting Services in progress should be completed;
(b) Consultant will deliver to AVROBIO all Work Product made through expiration or termination; (c) AVROBIO will pay Consultant any monies due and owing Consultant, up to the time of termination or expiration, for Consulting Services
properly performed and all authorized expenses actually incurred; (d) Consultant will immediately return to AVROBIO all AVROBIO Materials and other Confidential Information and copies thereof provided to or made by Consultant under this
Agreement; and (e) the terms, conditions and obligations under Sections 4 through 11 will survive expiration or termination of this Agreement. For the avoidance of doubt, if this Agreement is terminated for any reason other than subsection
(i) above, the Employment Agreement attached as Exhibit B shall be void ab initio and shall not become effective. 
  

	11.	 Miscellaneous. 

 

	 	(a)	 Independent Contractor. The parties understand and agree that Consultant is an independent
contractor and not an agent or employee of AVROBIO. Consultant has no authority to obligate AVROBIO by contract or otherwise. Consultant will not be eligible for any employee benefits of AVROBIO and expressly waives any rights to any employee
benefits. Consultant will bear sole responsibility for paying and reporting Consultant’s applicable federal and state income taxes, social security taxes, unemployment insurance, workers’ compensation, and health or disability insurance,
retirement benefits, and other welfare or pension benefits, if any, including those of any employee or representative of Consultant performing Consulting Services hereunder as applicable, and indemnifies and holds AVROBIO harmless from and against
any liability with respect to such taxes, benefits and other matters. 

  

	 	(b)	 Use of Name. Consultant consents to the use by AVROBIO of Consultant’s name on its website,
in press releases, company brochures, offering documents, presentations, reports or other documents in printed or electronic form, and any documents filed with or submitted to any governmental or regulatory agency or any securities exchange or
listing entity; provided, that such materials or presentations accurately describe the nature of Consultant’s relationship with or contribution to AVROBIO. 

  
 Page 4 of 9 

-CONFIDENTIAL- 

	 	(c)	 Entire Agreement. This Agreement contains the entire agreement of the parties with regard to its
subject matter, and supersedes all prior or contemporaneous written or oral representations, agreements and understandings between the parties relating to that subject matter. This Agreement may be changed only by a writing signed by Consultant and
an authorized representative of AVROBIO. 

  

	 	(d)	 Certain Disclosures and Transparency. Consultant acknowledges that AVROBIO and its affiliates are
required to abide by federal and state disclosure laws and certain transparency policies governing their activities including providing reports to the government and to the public concerning financial or other relationships with healthcare
providers. Consultant agrees that AVROBIO and its affiliates may, in their sole discretion, disclose information about this Agreement and about Consultant’s Consulting Services including those relating to healthcare providers and any
compensation paid to healthcare providers pursuant to this Agreement. Consultant agrees to promptly supply information reasonably requested by AVROBIO for disclosure purposes. 

 

	 	(e)	 Assignment and Binding Effect. The Consulting Services to be provided by Consultant are personal
in nature. Consultant may not assign or transfer this Agreement or any of Consultant’s rights or obligations hereunder. In no event will Consultant assign or delegate responsibility for actual performance of the Consulting Services to any third
party. AVROBIO may transfer or assign this Agreement, in whole or in part, without the prior written consent of Consultant. Any purported assignment or transfer in violation of this Section is void. This Agreement will be binding upon and inure to
the benefit of the parties and their respective legal representatives, heirs, successors and permitted assigns. 

  

	 	(f)	 Notices. All notices required or permitted under this Agreement must be in writing and must be
given by directing the notice to the address for the receiving party set forth in this Agreement or at such other address as the receiving party may specify in writing under this procedure. Notices to AVROBIO will be marked “Attention:
President & CEO”. All notices must be given (i) by personal delivery, with receipt acknowledged, (ii) by prepaid certified or registered mail, return receipt requested, or (iii) by prepaid recognized next business day
delivery service. Notices will be effective upon receipt or at a later date stated in the notice. 

  

	 	(g)	 Governing Law. This Agreement and any disputes relating to or arising out of this Agreement will
be governed by, construed, and interpreted in accordance with the internal laws of the Commonwealth of Massachusetts, USA without regard to any choice of law principle that would require the application of the law of another jurisdiction. The
parties agree to submit to the exclusive jurisdiction of the state and federal courts located in the Commonwealth of Massachusetts, USA and waive any defense of inconvenient forum to the maintenance of any action or proceeding in such courts.

  

	 	(h)	 Severability; Reformation. Each provision in this Agreement is independent and severable from the
others, and no provision will be rendered unenforceable because any other provision is found by a proper authority to be invalid or unenforceable in whole or in part. If any provision of this Agreement is found by such an authority to be invalid or
unenforceable in whole or in part, such provision shall be changed and interpreted so as to best accomplish the objectives of such unenforceable or invalid provision and the intent of the parties, within the limits of applicable law.

  

	 	(i)	 No Strict Construction; Headings. This Agreement has been prepared jointly and will not be
strictly construed against either party. The section headings are included solely for convenience of reference and will not control or affect the meaning or interpretation of any of the provisions of this Agreement. 

  
 Page 5 of 9 

-CONFIDENTIAL- 

	 	(j)	 Waivers. Any delay in enforcing a party’s rights under this Agreement, or any waiver as to a
particular default or other matter, will not constitute a waiver of such party’s rights to the future enforcement of its rights under this Agreement, except with respect to an express written waiver relating to a particular matter for a
particular period of time signed by Consultant and an authorized representative of the waiving party, as applicable. 

  

	 	(k)	 Remedies. Consultant agrees that (i) AVROBIO may be irreparably injured by a breach of this
Agreement by Consultant; (ii) money damages would not be an adequate remedy for any such breach; (iii) as a remedy for any such breach AVROBIO will be entitled to seek equitable relief, including injunctive relief and specific performance,
without being required by Consultant to post a bond; and (iv) such remedy will not be the exclusive remedy for any breach of this Agreement. 

  

	 	(l)	 Counterparts. This Agreement may be executed in any number of counterparts, each of which will be
deemed an original, but all of which together will constitute one and the same instrument. A facsimile or portable document format (“.pdf”) copy of this Agreement, including the signature pages, will be deemed an original.

 [Signature page follows] 

  
 Page 6 of 9 

-CONFIDENTIAL- 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the Effective Date. 

 

			
	AVROBIO, INC.
		
	By: 	 	/s/ Geoff MacKay

 
			
	Name: Geoff MacKay
	Title: President & CEO

  

	
	CONSULTANT
	
	On behalf of BIVO and in her individual capacity:
	
	/s/ Birgitte Volck
	Birgitte Volck, MD

  
 Page 7 of 9 

-CONFIDENTIAL- 

 EXHIBIT A 
  

	1.	 Consulting Services: 

Consultant will provide the following Consulting Services to AVROBIO: 

Birgitte Volck, MD shall serve as AVROBIO’s President of Research and Development. The Consulting Services shall be performed in Denmark.

  

	2.	 Compensation: 

Fees: As full compensation for the Consulting Services performed in accordance with the terms of this Agreement, AVROBIO will pay
Consultant $37,916.67 per month during the Term. 
 Expenses: AVROBIO will reimburse Consultant for any
pre-approved expenses actually incurred by Consultant in connection with the provision of Consulting Services. Requests for reimbursement will be in a form reasonably acceptable to AVROBIO, will include
supporting documentation and will accompany Consultant’s invoices. 
 Invoicing: No later than the last day of each calendar
month, Consultant will invoice AVROBIO for Consulting Services rendered and related expenses incurred during the preceding month. Invoices should reference this Agreement and be e-mailed to [***]. Invoices
will contain such detail as AVROBIO may reasonably require and will be payable in U.S. Dollars. Undisputed payments will be made by AVROBIO within thirty (30) days after AVROBIO’s receipt of Consultant’s invoice, request for
reimbursement and all supporting documentation. 

  
 Page 8 of 9 

-CONFIDENTIAL- 

 EXHIBIT B 

Employment Agreement 

  
 Page 9 of 9 

-CONFIDENTIAL-EX-10.15

 Exhibit 10.15 

AVROBIO, INC. 
 EMPLOYMENT
AGREEMENT 
 This Employment Agreement (“Agreement”) is made as of the 17th day of December, 2018, between AVROBIO, Inc., a
Delaware corporation (together with its subsidiaries, the “Company”), and Birgitte Volck, MD (the “Executive”). 

WHEREAS, the Company desires to employ the Executive and the Executive desires to be employed by the Company commencing on the date
immediately following the date of termination of the Consulting Agreement entered into by the Company and the Executive dated December 17, 2018 (the “Consulting Agreement”), subject to Section 21 of this Agreement. The
Executive’s first day of employment shall be the “Effective Date” of this Agreement. 
 WHEREAS, to protect the
Company’s proprietary information and goodwill, as a condition of Executive’s employment, the Executive and the Company will become parties to Employee Confidentiality, Assignment and Noncompetition Agreement (the “Restrictive
Covenants Agreement”) which is being provided to Executive along with this Agreement and at least ten (10) business days before the Effective Date. Executive has a right to consult with counsel prior to signing the Restrictive Covenants
Agreement. 
 NOW, THEREFORE, in consideration of the mutual covenants and agreements herein contained and other good and valuable
consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows: 
 1. Employment. 

(a) Term. The term of this Agreement shall commence on the Effective Date and continue until terminated in accordance with the
provisions hereof (the “Term”). The Executive’s employment with the Company will be “at will,” meaning that the Executive’s employment may be terminated by the Company or the Executive at any time and for any reason
subject to the terms of this Agreement. 
 (b) Position and Duties. During the Term, the Executive shall serve as the President of
Research and Development of the Company, and shall have supervision and control over and responsibility for the day-to-day business and affairs of the research and
development department of the Company and shall have such other powers and duties as may from time to time be prescribed by the Board of Directors of the Company (the “Board”), the Chief Executive Officer of the Company (the
“CEO”) or other authorized executive. The Executive shall devote her full working time and efforts to the business and affairs of the Company. Notwithstanding the foregoing, the Executive may serve on other boards of directors, with the
approval of the Board, or engage in religious, charitable or other community activities as long as such services and activities are disclosed to the Board and do not materially interfere with the Executive’s performance of her duties to the
Company as provided in this Agreement. For the avoidance of doubt, the Executive may continue to serve in the roles set forth on Schedule 1 hereto without the necessity of further approval from the Board, provided that no conflicts result in the
future from the Executive’s service in such role. 

 2. Compensation and Related Matters. 

(a) Base Salary. During the Term, the Executive’s annual base salary rate shall be $455,000. The Executive’s base salary
shall be reviewed annually by the Board or the Compensation Committee of the Board (the “Compensation Committee”). The base salary in effect at any given time is referred to herein as “Base Salary.” The Base Salary shall be
payable in a manner that is consistent with the Company’s usual payroll practices for executive officers. 
 (b) Incentive
Compensation. During the Term, the Executive shall be eligible to receive cash incentive compensation as determined by the Board or the Compensation Committee from time to time. The Executive’s initial target annual incentive
compensation shall be fifty percent (50%) of her Base Salary (as in effect at any time, the “Target Annual Incentive Compensation”). To earn incentive compensation, the Executive must be employed by the Company on the day such incentive
compensation is paid. 
 (c) Expenses. The Executive shall be entitled to receive prompt reimbursement for all reasonable expenses
incurred by the Executive during the Term in performing services hereunder, in accordance with the policies and procedures then in effect and established by the Company for its senior officers. 

(d) Commuting and Living Expenses. The Company shall also reimburse the Executive for the following reasonable costs incurred by her,
subject to the Executive’s timely submission of applicable documentation pursuant to the sentence below: (i) reimbursement for up to $5,000 per month for housing in the Greater Boston area; (ii) up to $5,000 per round-trip travel from
Denmark to the United States; (iii) up to $20,000 per year for tax advice, plus any additional amounts pre-approved by the Company in its discretion; (iv) up to $200 per month for heat and
electricity; (v) the Executive’s monthly cellphone bill; (v) transportation via taxi or car-sharing service to and from the airport and worksite; (vi) the Executive’s annual Global
Entry Fee; and (vii) reasonable legal fees related to obtaining the Executive’s O-1 visa. All expenses must be submitted to the Company on a monthly basis, no later than the middle of the month
following the month in which such expenses were incurred. 
 (e) Other Benefits. During the Term, the Executive shall be eligible to
participate in or receive benefits under the Company’s employee benefit plans in effect from time to time, subject to the terms of such plans. Additionally, during the Term, the Executive shall be eligible to receive such benefits and
perquisites as those made available to the other employees of the Company generally. 
 (f) Place of Performance. Unless otherwise
agreed to by the Executive and the Company, the Executive shall perform her duties for the Company on an alternating schedule between the Company’s Massachusetts office, currently located in Cambridge, Massachusetts, and in Denmark; provided,
however, that the Executive shall also be required to travel to the extent reasonably required to perform her job duties; provided further that the Executive shall spend no less than 50% of her working time at the Company’s Massachusetts
office, unless previously agreed to in writing (which may include email) by the CEO, who shall not unreasonably withhold his agreement. When the Executive is performing services in Denmark she will not enter into any agreements on behalf of the
Company or otherwise bind with Company without the prior written consent of the CEO or another authorized executive. 

  
 2 

 (g) Vacations. During the Term, the Executive shall be entitled to paid vacation in
accordance with the Company’s policies and procedures, which shall be a minimum of 20 days in addition to the Company’s paid holidays. The Executive shall also be entitled to all paid holidays given by the Company to its executive
officers. 
 (h) Equity. The Executive shall also be eligible to participate in the Company’s equity incentive plan,
subject to approval by the Board or Compensation Committee. As a material inducement to the Executive entering into this Agreement and becoming an employee of the Company, and subject to approval by the Board or Compensation Committee, the Company
will grant the Executive an option to purchase 293,000 shares of the Company’s common stock (“New Hire Award”). The New Hire Award shall vest over four years, with twenty-five percent of the New Hire Award vesting on the one-year anniversary of the date of this Agreement and the remaining shares vesting in thirty-six equal monthly installments following the
one-year anniversary of the date of this Agreement, subject to the Executive’s continued service relationship with the Company. The New Hire Award shall be granted in the form of a non-qualified stock option as an inducement grant consistent with the requirements of NASDAQ Stock Market Rule 5635(c)(4) instead of pursuant to the Company’s existing equity plan. The New Hire Award will be
governed by the terms and conditions of an award agreement (such documents, together with any other equity awards held by the Executive and the applicable award agreements and the Company’s applicable equity incentive plan(s), the “Equity
Documents”); provided, however, and notwithstanding anything to the contrary in the Equity Documents, Section 4(b)(ii) or Section 5(a)(ii) of this Agreement (as applicable) shall apply in the event of a termination by the Company
without Cause or by the Executive for Good Reason (as such terms are defined below). To the extent permitted under the NASDAQ Rules, the Company shall issue the New Hire Award at the commencement of the Executive’s consultancy pursuant to the
Consulting Agreement, and such issuance shall be in full satisfaction of the Company’s obligations pursuant to this Section 2(h). 

3. Termination. During the Term, the Executive’s employment hereunder may be terminated without any breach of this Agreement under
the following circumstances: 
 (a) Death. The Executive’s employment hereunder shall terminate upon her death. 

(b) Disability. The Company may terminate the Executive’s employment if she is disabled and unable to perform the essential
functions of the Executive’s then existing position or positions under this Agreement with or without reasonable accommodation for a period of 180 days (which need not be consecutive) in any 12-month
period. If any question shall arise as to whether during any period the Executive is disabled so as to be unable to perform the essential functions of the Executive’s then existing position or positions with or without reasonable accommodation,
the Executive may, and at the request of the Company shall, submit to the Company a certification in reasonable detail by a physician selected by the 

  
 3 

 
Company to whom the Executive or the Executive’s guardian has no reasonable objection as to whether the Executive is so disabled or how long such disability is expected to continue, and such
certification shall for the purposes of this Agreement be conclusive of the issue. The Executive shall cooperate with any reasonable request of the physician in connection with such certification. If such question shall arise and the Executive shall
fail to submit such certification, the Company’s determination of such issue shall be binding on the Executive. Nothing in this Section 3(b) shall be construed to waive the Executive’s rights, if any, under existing law including,
without limitation, the Family and Medical Leave Act of 1993, 29 U.S.C. §2601 et seq. and the Americans with Disabilities Act, 42 U.S.C. §12101 et seq. 

(c) Termination by Company for Cause. The Company may terminate the Executive’s employment hereunder for Cause. For purposes of
this Agreement, “Cause” shall mean: (i) conduct by the Executive constituting a material act of misconduct in connection with the performance of her duties, including, without limitation, misappropriation of funds or property of the
Company or any of its subsidiaries or affiliates other than the occasional, customary and de minimis use of Company property for personal purposes; (ii) the commission by the Executive of any felony or a misdemeanor involving moral turpitude,
material deceit or dishonesty, or fraud, or any conduct by the Executive that would reasonably be expected to result in material injury or reputational harm to the Company or any of its subsidiaries or affiliates if she were retained in her
position; (iii) continued non-performance by the Executive of her duties hereunder (other than by reason of the Executive’s physical or mental illness, incapacity or disability) which has continued
for more than 30 days following written notice (with a reasonably detailed summary of such alleged non-performance specified) of such non-performance from the
Company’s CEO; (iv) a breach by the Executive of any of the provisions incorporated into or contained in Section 7 of this Agreement; (v) a material violation by the Executive of the Company’s written employment policies; or
(vi) failure to cooperate with a bona fide internal investigation or an investigation by regulatory or law enforcement authorities, after being instructed by the Company to cooperate, or the willful destruction or failure to preserve documents
or other materials known to be relevant to such investigation or the inducement of others to fail to cooperate or to produce documents or other materials in connection with such investigation. 

(d) Termination Without Cause. The Company may terminate the Executive’s employment hereunder at any time without Cause. Any
termination by the Company of the Executive’s employment under this Agreement which does not constitute a termination for Cause under Section 3(c) and does not result from the death or disability of the Executive under Section 3(a) or
(b) shall be deemed a termination without Cause. 
 (e) Termination by the Executive. The Executive may terminate her employment
hereunder at any time for any reason, including but not limited to Good Reason. For purposes of this Agreement, “Good Reason” shall mean that the Executive has complied with the “Good Reason Process” (hereinafter defined)
following the occurrence of any of the following events: (i) a material diminution in the Executive’s responsibilities, authority or duties or reporting relationship; (ii) a material diminution in the Executive’s Base Salary
except for across-the-board salary reductions based on the Company’s financial performance similarly affecting all or substantially all senior management employees
of the Company; (iii) a material change in the geographic location at which the Executive provides services to the Company; or 

  
 4 

 
(iv) a material breach of this Agreement by the Company. “Good Reason Process” shall mean that (i) the Executive reasonably determines in good faith that a “Good Reason”
condition has occurred; (ii) the Executive notifies the Company in writing of the first occurrence of the Good Reason condition within 60 days of the first occurrence of such condition; (iii) the Executive cooperates in good faith with the
Company’s efforts, for a period not less than 30 days following such notice (the “Cure Period”), to remedy the condition; (iv) notwithstanding such efforts, the Good Reason condition continues to exist; and (v) the Executive
terminates her employment within 60 days after the end of the Cure Period. If the Company cures the Good Reason condition during the Cure Period, Good Reason shall be deemed not to have occurred. 

(f) Notice of Termination. Except for termination as specified in Section 3(a), any termination of the Executive’s employment
by the Company or any such termination by the Executive shall be communicated by written Notice of Termination to the other party hereto. For purposes of this Agreement, a “Notice of Termination” shall mean a notice which shall indicate
the specific termination provision in this Agreement relied upon. 
 (g) Date of Termination. “Date of Termination” shall
mean: (i) if the Executive’s employment is terminated by her death, the date of her death; (ii) if the Executive’s employment is terminated on account of disability under Section 3(b) or by the Company for Cause under
Section 3(c), the date on which Notice of Termination is given; (iii) if the Executive’s employment is terminated by the Company under Section 3(d), the date on which a Notice of Termination is given; (iv) if the
Executive’s employment is terminated by the Executive under Section 3(e) without Good Reason, 30 days after the date on which a Notice of Termination is given, and (v) if the Executive’s employment is terminated by the Executive
under Section 3(e) with Good Reason, the date on which a Notice of Termination is given after the end of the Cure Period. Notwithstanding the foregoing, in the event that the Executive gives a Notice of Termination to the Company, the Company
may unilaterally accelerate the Date of Termination and such acceleration shall not result in a termination by the Company for purposes of this Agreement. 

4. Compensation Upon Termination. 

(a) Termination Generally. If the Executive’s employment with the Company is terminated for any reason, the Company shall pay or
provide to the Executive (or to her authorized representative or estate) (i) any Base Salary earned through the Date of Termination, unpaid expense reimbursements (subject to, and in accordance with, Section 2(c) of this Agreement) and
unused vacation that accrued through the Date of Termination on or before the time required by law but in no event more than 30 days after the Executive’s Date of Termination; and (ii) any vested benefits the Executive may have under any
employee benefit plan of the Company through the Date of Termination, which vested benefits shall be paid and/or provided in accordance with the terms of such employee benefit plans (collectively, the “Accrued Benefit”). 

  
 5 

 (b) Termination by the Company Without Cause or by the Executive with Good Reason.
During the Term, if the Executive’s employment is terminated by the Company without Cause as provided in Section 3(d), or the Executive terminates her employment for Good Reason as provided in Section 3(e), then the Company shall pay
the Executive her Accrued Benefit. In addition, subject to the Executive signing a separation agreement containing, among other provisions, a general release of claims in favor of the Company and related persons and entities, confidentiality, return
of property and non-disparagement, a reaffirmation of all of the Executive’s Continuing Obligations and, in the Company’s sole discretion, a one-year
post-employment noncompetition agreement, and that shall provide that if the Executive breaches any of the Executive’s Continuing Obligations, all payments of the Severance Amount shall immediately cease, in a form and manner satisfactory to
the Company (the “Separation Agreement and Release”) and the Separation Agreement and Release becoming irrevocable (after a seven (7) business day revocation period) and fully effective and, if applicable, the Executive resigning as a
member of the Board of Directors, all within 60 days after the Date of Termination (or such shorter time period provided in the Separation Agreement and Release): 

(i) the Company shall pay the Executive an amount equal to 0.75 times the sum of the Executive’s Base Salary (the
“Severance Amount”) provided in the event the Executive is entitled to any payments pursuant to the Restrictive Covenants Agreement, the Severance Amount received in any calendar year will be reduced by the amount the Executive is paid in
the same such calendar year pursuant to the Restrictive Covenants Agreement (the “Restrictive Covenants Agreement Setoff”); 

(ii) notwithstanding anything to the contrary in any applicable option agreement or stock-based award agreement, all time-based
stock options and other time-based stock-based awards held by the Executive in which such stock option or other stock-based award would have vested if the Executive had remained employed for an additional nine months following the Date of
Termination shall vest and become exercisable or nonforfeitable as of the Date of Termination; 
 (iii) if the Executive was
participating in the Company’s group health plan immediately prior to the Date of Termination and elects COBRA health continuation, then the Company shall pay to the Executive a monthly cash payment for nine months or the Executive’s COBRA
health continuation period, whichever ends earlier, in an amount equal to the monthly employer contribution that the Company would have made to provide health insurance to the Executive if the Executive had remained employed by the Company; and 

(iv) the amounts payable under Section 4(b)(i) and (iii) shall be paid out in substantially equal installments in
accordance with the Company’s payroll practice over nine months commencing within 60 days after the Date of Termination; provided, however, that if the 60-day period begins in one calendar
year and ends in a second calendar year, the Severance Amount shall begin to be paid in the second calendar year by the last day of such 60-day period; provided, further, that the initial payment shall include
a catch-up payment to cover amounts retroactive to the day immediately following the Date of Termination. Each payment pursuant to this Agreement is intended to constitute a separate payment for purposes of
Treasury Regulation Section 1.409A-2(b)(2). 

  
 6 

 5. Change in Control Payment. The provisions of this Section 5 set forth certain
terms of an agreement reached between the Executive and the Company regarding the Executive’s rights and obligations upon the occurrence of a Change in Control of the Company. In the event of a Change in Control during the Term, all time-based
stock options and other time-based stock-based awards held by the Executive as of the Effective Date that were granted to the Executive at least 12 months prior to the Effective Date shall immediately accelerate and become fully exercisable or
nonforfeitable as of immediately prior to such Change in Control. These provisions are intended to assure and encourage in advance the Executive’s continued attention and dedication to her assigned duties and her objectivity during the pendency
and after the occurrence of any such event. These provisions shall apply in lieu of, and expressly supersede, the provisions of Section 4(b) regarding severance pay and benefits upon a termination of employment, if such termination of
employment occurs within three months prior to or 18 months after the occurrence of the first event constituting a Change in Control. These provisions shall terminate and be of no further force or effect beginning 18 months after the occurrence of a
Change in Control. 
 (a) Change in Control. During the Term, if within three months prior to or 18 months after a Change in Control,
the Executive’s employment is terminated by the Company without Cause as provided in Section 3(d) or the Executive terminates her employment for Good Reason as provided in Section 3(e), then, subject to the signing of the Separation
Agreement and Release by the Executive and the Separation Agreement and Release becoming irrevocable and fully effective and, if applicable, the Executive resigning as a member of the Board of Directors, all within 60 days after the Date of
Termination (or such shorter time period provided in the Separation Agreement and Release): 
 (i) the Company shall pay the
Executive a lump sum in cash in an amount equal to one times the sum of (A) the Executive’s current Base Salary (or the Executive’s Base Salary in effect immediately prior to the Change in Control, if higher) and (B) the
Executive’s Target Annual Incentive Compensation then in effect (together the “Change in Control Payment”), provided the Change in Control Payment shall be reduced by the amount of the Restrictive Covenants Agreement Setoff, if
applicable, paid or to be paid in the same calendar year; 
 (ii) notwithstanding anything to the contrary in any applicable
option agreement or stock-based award agreement, all time-based stock options and other time-based stock-based awards held by the Executive shall immediately accelerate and become fully exercisable or nonforfeitable as of the Date of Termination;

 (iii) if the Executive was participating in the Company’s group health plan immediately prior to the Date of
Termination and elects COBRA health continuation, then the Company shall pay to the Executive a monthly cash payment for twelve months or the Executive’s COBRA health continuation period, whichever ends earlier, in an amount equal to the
monthly employer contribution that the Company would have made to provide health insurance to the Executive if the Executive had remained employed by the Company; and 

(iv) The amounts payable under Section 5(a)(i) and (iii) shall be paid or commence to be paid within 60 days after
the Date of Termination; provided, however, that if the 60-day period begins in one calendar year and ends in a second calendar year, such payment shall be paid or commence to be paid in the second calendar
year by the last day of such 60-day period. 

  
 7 

 (b) Additional Limitation. 

(i) Anything in this Agreement to the contrary notwithstanding, in the event that the amount of any compensation, payment or
distribution by the Company to or for the benefit of the Executive, whether paid or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise, calculated in a manner consistent with Section 280G of the
Internal Revenue Code of 1986, as amended (the “Code”) and the applicable regulations thereunder (the “Aggregate Payments”), would be subject to the excise tax imposed by Section 4999 of the Code, then the Aggregate Payments
shall be reduced (but not below zero) so that the sum of all of the Aggregate Payments shall be $1.00 less than the amount at which the Executive becomes subject to the excise tax imposed by Section 4999 of the Code; provided that such
reduction shall only occur if it would result in the Executive receiving a higher After Tax Amount (as defined below) than the Executive would receive if the Aggregate Payments were not subject to such reduction. In such event, the Aggregate
Payments shall be reduced in the following order, in each case, in reverse chronological order beginning with the Aggregate Payments that are to be paid the furthest in time from consummation of the transaction that is subject to Section 280G
of the Code: (1) cash payments not subject to Section 409A of the Code; (2) cash payments subject to Section 409A of the Code; (3) equity-based payments and acceleration; and
(4) non-cash forms of benefits; provided that in the case of all the foregoing Aggregate Payments all amounts or payments that are not subject to calculation under Treas. Reg. §1.280G-1, Q&A-24(b) or (c) shall be reduced before any amounts that are subject to calculation under Treas. Reg.
§1.280G-1, Q&A-24(b) or (c). 
 (ii)
For purposes of this Section 5(b), the “After Tax Amount” means the amount of the Aggregate Payments less all federal, state, and local income, excise and employment taxes imposed on the Executive as a result of the Executive’s
receipt of the Aggregate Payments. For purposes of determining the After Tax Amount, the Executive shall be deemed to pay federal income taxes at the highest marginal rate of federal income taxation applicable to individuals for the calendar year in
which the determination is to be made, and state and local income taxes at the highest marginal rates of individual taxation in each applicable state and locality, net of the maximum reduction in federal income taxes which could be obtained from
deduction of such state and local taxes. 
 (iii) The determination as to whether a reduction in the Aggregate Payments shall
be made pursuant to Section 5(b)(i) shall be made by a nationally recognized accounting firm selected by the Company (the “Accounting Firm”), which shall provide detailed supporting calculations both to the Company and the Executive
within 15 business days of the Date of Termination, if applicable, or at such earlier time as is reasonably requested by the Company or the Executive. Any determination by the Accounting Firm shall be binding upon the Company and the Executive. 

  
 8 

 (c) Definitions. For purposes of this Section 5, the following terms shall have
the following meanings: 
 “Change in Control” shall mean any of the following: 

(i) any “person,” as such term is used in Sections 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended
(the “Act”) (other than the Company, any of its subsidiaries, or any trustee, fiduciary or other person or entity holding securities under any employee benefit plan or trust of the Company or any of its subsidiaries), together with all
“affiliates” and “associates” (as such terms are defined in Rule 12b-2 under the Act) of such person, shall become the “beneficial owner” (as such term is defined in Rule 13d-3 under the Act), directly or indirectly, of securities of the Company representing 50 percent or more of the combined voting power of the Company’s then outstanding securities having the right to vote
in an election of the Board (“Voting Securities”) (in such case other than as a result of an acquisition of securities directly from the Company); or 

(ii) the date a majority of the members of the Board is replaced during any 12-month
period by directors whose appointment or election is not endorsed by a majority of the members of the Board before the date of the appointment or election; or 

(iii) the consummation of (A) any consolidation or merger of the Company where the stockholders of the Company,
immediately prior to the consolidation or merger, would not, immediately after the consolidation or merger, beneficially own (as such term is defined in Rule 13d-3 under the Act), directly or indirectly,
shares representing in the aggregate more than 50 percent of the voting shares of the Company issuing cash or securities in the consolidation or merger (or of its ultimate parent corporation, if any), or (B) any sale or other transfer (in
one transaction or a series of transactions contemplated or arranged by any party as a single plan) of all or substantially all of the assets of the Company. 

Notwithstanding the foregoing, a “Change in Control” shall not be deemed to have occurred for purposes of the foregoing clause
(i) solely as the result of an acquisition of securities by the Company which, by reducing the number of shares of Voting Securities outstanding, increases the proportionate number of Voting Securities beneficially owned by any person to
50 percent or more of the combined voting power of all of the then outstanding Voting Securities; provided, however, that if any person referred to in this sentence shall thereafter become the beneficial owner of any additional shares of Voting
Securities (other than pursuant to a stock split, stock dividend, or similar transaction or as a result of an acquisition of securities directly from the Company) and immediately thereafter beneficially owns 50 percent or more of the combined
voting power of all of the then outstanding Voting Securities, then a “Change in Control” shall be deemed to have occurred for purposes of the foregoing clause (i). 

  
 9 

 6. Section 409A. 

(a) Anything in this Agreement to the contrary notwithstanding, if at the time of the Executive’s separation from service within the
meaning of Section 409A of the Code, the Company determines that the Executive is a “specified employee” within the meaning of Section 409A(a)(2)(B)(i) of the Code, then to the extent any payment or benefit that the Executive
becomes entitled to under this Agreement on account of the Executive’s separation from service would be considered deferred compensation otherwise subject to the 20 percent additional tax imposed pursuant to Section 409A(a) of the
Code as a result of the application of Section 409A(a)(2)(B)(i) of the Code, such payment shall not be payable and such benefit shall not be provided until the date that is the earlier of (A) six months and one day after the
Executive’s separation from service, or (B) the Executive’s death. If any such delayed cash payment is otherwise payable on an installment basis, the first payment shall include a catch-up
payment covering amounts that would otherwise have been paid during the six-month period but for the application of this provision, and the balance of the installments shall be payable in accordance with their
original schedule. 
 (b) All in-kind benefits provided and expenses eligible for reimbursement
under this Agreement shall be provided by the Company or incurred by the Executive during the time periods set forth in this Agreement. All reimbursements shall be paid as soon as administratively practicable, but in no event shall any reimbursement
be paid after the last day of the taxable year following the taxable year in which the expense was incurred. The amount of in-kind benefits provided or reimbursable expenses incurred in one taxable year shall
not affect the in-kind benefits to be provided or the expenses eligible for reimbursement in any other taxable year (except for any lifetime or other aggregate limitation applicable to medical expenses). Such
right to reimbursement or in-kind benefits is not subject to liquidation or exchange for another benefit. 

(c) To the extent that any payment or benefit described in this Agreement constitutes
“non-qualified deferred compensation” under Section 409A of the Code, and to the extent that such payment or benefit is payable upon the Executive’s termination of employment, then such
payments or benefits shall be payable only upon the Executive’s “separation from service.” The determination of whether and when a separation from service has occurred shall be made in accordance with the presumptions set forth in
Treasury Regulation Section 1.409A-1(h). 
 (d) The parties intend that this Agreement will be
administered in accordance with Section 409A of the Code. To the extent that any provision of this Agreement is ambiguous as to its compliance with Section 409A of the Code, the provision shall be read in such a manner so that all payments
hereunder comply with Section 409A of the Code. Each payment pursuant to this Agreement is intended to constitute a separate payment for purposes of Treasury Regulation Section 1.409A-2(b)(2). The
parties agree that this Agreement may be amended, as reasonably requested by either party, and as may be necessary to fully comply with Section 409A of the Code and all related rules and regulations in order to preserve the payments and
benefits provided hereunder without additional cost to either party. 
 (e) The Company makes no representation or warranty and shall have
no liability to the Executive or any other person if any provisions of this Agreement are determined to constitute deferred compensation subject to Section 409A of the Code but do not satisfy an exemption from, or the conditions of, such
Section. 

  
 10 

 7. Confidential Information, Noncompetition and Cooperation. 

(a) Restrictive Covenants Agreement. The Executive acknowledges and agrees that in consideration and as a condition of the
Executive’s employment by the Company and in exchange for, among other things, the benefits contained in this Agreement, the Executive will enter into the Restrictive Covenants Agreement, attached hereto as Exhibit A, the terms of which
are incorporated by reference as material terms of this Agreement. For purposes of this Agreement, the obligations in this Section 7 and those that arise in the Restrictive Covenants Agreement and any other agreement relating to
confidentiality, assignment of inventions, or other restrictive covenants shall collectively be referred to as the “Continuing Obligations.” 

(b) Third-Party Agreements and Rights. The Executive hereby confirms that the Executive is not bound by the terms of any agreement with
any previous employer or other party which restricts in any way the Executive’s use or disclosure of information or the Executive’s engagement in any business. The Executive represents to the Company that the Executive’s execution of
this Agreement, the Executive’s employment with the Company and the performance of the Executive’s proposed duties for the Company will not violate any obligations the Executive may have to any such previous employer or other party. In the
Executive’s work for the Company, the Executive will not disclose or make use of any information in violation of any agreements with or rights of any such previous employer or other party, and the Executive will not bring to the premises of the
Company any copies or other tangible embodiments of non-public information belonging to or obtained from any such previous employment or other party. 

(c) Litigation and Regulatory Cooperation. During and after the Executive’s employment, the Executive shall reasonably cooperate
with the Company in the defense or prosecution of any claims or actions now in existence or which may be brought in the future against or on behalf of the Company which relate to events or occurrences that transpired while the Executive was employed
by the Company. The Executive’s full cooperation in connection with such claims or actions shall include, but not be limited to, being available to meet with counsel to prepare for discovery or trial and to act as a witness on behalf of the
Company at mutually convenient times, taking into consideration Executive’s then current business and personal commitments. During and after the Executive’s employment, the Executive also shall cooperate fully with the Company in
connection with any investigation or review of any federal, state or local regulatory authority as any such investigation or review relates to events or occurrences that transpired while the Executive was employed by the Company. The Company shall
reimburse the Executive for any reasonable out-of-pocket expenses incurred in connection with the Executive’s performance of obligations pursuant to this
Section 7(c). 
 (d) Relief. The Executive agrees that it would be difficult to measure any damages caused to the Company which
might result from any breach by the Executive of the promises incorporated into or set forth in this Section 7, and that in any event money damages would be an inadequate remedy for any such breach. Accordingly, subject to Section 8 of
this Agreement, the Executive agrees that if the Executive breaches, or proposes to breach, any portion of this Agreement, the Company shall be entitled, in addition to all other remedies that it may have, to an injunction or other appropriate
equitable relief to restrain any such breach without showing or proving any actual damage to the Company. In addition, in the event the 

  
 11 

 
Executive breaches this Section 7 or the provisions incorporated herein during a period when she is receiving severance payments pursuant to Section 4 or Section 5 hereof, the
Company shall have the right to suspend or terminate such severance payments. Such suspension or termination shall not limit the Company’s other options with respect to relief for such breach and shall not relieve the Executive of her duties
under this Agreement. 
 (e) Protected Disclosures and Other Protected Action. Nothing contained in this Agreement limits the
Executive’s ability to communicate with any federal, state or local governmental agency or commission, including to provide documents or other information, without notice to the Company. 

8. Arbitration of Disputes. Any controversy or claim arising out of or relating to this Agreement or the breach thereof or otherwise
arising out of the Executive’s employment or the termination of that employment (including, without limitation, any claims of unlawful employment discrimination whether based on age or otherwise) shall, to the fullest extent permitted by law,
be settled by arbitration in any forum and form agreed upon by the parties or, in the absence of such an agreement, under the auspices of the American Arbitration Association (“AAA”) in Boston, Massachusetts in accordance with the
Employment Dispute Resolution Rules of the AAA, including, but not limited to, the rules and procedures applicable to the selection of arbitrators. In the event that any person or entity other than the Executive or the Company may be a party with
regard to any such controversy or claim, such controversy or claim shall be submitted to arbitration subject to such other person or entity’s agreement. Judgment upon the award rendered by the arbitrator may be entered in any court having
jurisdiction thereof. This Section 8 shall be specifically enforceable. Notwithstanding the foregoing, this Section 8 shall not preclude either party from pursuing a court action for the sole purpose of enforcing the Restrictive Covenants
Agreement or obtaining a temporary restraining order or a preliminary injunction in circumstances in which such relief is appropriate; provided that any other relief shall be pursued through an arbitration proceeding pursuant to this Section 8.

 9. Consent to Jurisdiction. To the extent that any court action is permitted consistent with or to enforce Section 8 of this
Agreement, the parties hereby consent to the jurisdiction of the Superior Court of the Commonwealth of Massachusetts and the United States District Court for the District of Massachusetts. Accordingly, with respect to any such court action, the
Executive (a) submits to the personal jurisdiction of such courts; (b) consents to service of process; and (c) waives any other requirement (whether imposed by statute, rule of court, or otherwise) with respect to personal
jurisdiction or service of process. 
 10. Integration. This Agreement and the Restrictive Covenants Agreement constitute the entire
agreement between the parties with respect to the subject matter hereof and supersede all prior agreements between the parties concerning such subject matter, including without limitation the Consulting Agreement, provided that Sections 6 through 9
of the Consulting Agreement, the Equity Documents (if the New Hire Award was granted prior to the Effective Date), as well as any agreements regarding confidentiality and assignment of inventions shall remain in full force and effect. 

  
 12 

 11. Withholding and Other Tax Matters. All payments made by the Company to the
Executive under this Agreement shall be net of any tax or other amounts required to be withheld by the Company under applicable law. The Company will report payments to Executive to taxing authorities to the extent it makes a good faith
determination that such reporting is required. Nothing in the Agreement shall be construed to require the Company to structure any compensation or benefit program to be tax advantageous for the Executive. The Executive agrees to make all required
tax payments in Denmark with respect to compensation received from the Company. 
 12. Successor to the Executive. This Agreement
shall inure to the benefit of and be enforceable by the Executive’s personal representatives, executors, administrators, heirs, distributees, devisees and legatees. In the event of the Executive’s death after her termination of employment
but prior to the completion by the Company of all payments due to her under this Agreement, the Company shall continue such payments to the Executive’s beneficiary designated in writing to the Company prior to her death (or to her estate, if
the Executive fails to make such designation). 
 13. Enforceability. If any portion or provision of this Agreement (including,
without limitation, any portion or provision of any section of this Agreement) shall to any extent be declared illegal or unenforceable by a court of competent jurisdiction, then the remainder of this Agreement, or the application of such portion or
provision in circumstances other than those as to which it is so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision of this Agreement shall be valid and enforceable to the fullest extent permitted by
law. 
 14. Survival. The provisions of this Agreement shall survive the termination of this Agreement and/or the termination of the
Executive’s employment to the extent necessary to effectuate the terms contained herein. 
 15. Waiver. No waiver of any
provision hereof shall be effective unless made in writing and signed by the waiving party. The failure of any party to require the performance of any term or obligation of this Agreement, or the waiver by any party of any breach of this Agreement,
shall not prevent any subsequent enforcement of such term or obligation or be deemed a waiver of any subsequent breach. 
 16.
Notices. Any notices, requests, demands and other communications provided for by this Agreement shall be sufficient if in writing and delivered in person or sent by a nationally recognized overnight courier service or by registered or
certified mail, postage prepaid, return receipt requested, to the Executive at the last address the Executive has filed in writing with the Company or, in the case of the Company, at its main offices, attention of the Board. 

17. Amendment. This Agreement may be amended or modified only by a written instrument signed by the Executive and by a duly authorized
representative of the Company. 
 18. Governing Law. This is a Massachusetts contract and shall be construed under and be governed in
all respects by the laws of the Commonwealth of Massachusetts, without giving effect to the conflict of laws principles thereof. 

  
 13 

 19. Counterparts. This Agreement may be executed in any number of counterparts, each
of which when so executed and delivered shall be taken to be an original; but such counterparts shall together constitute one and the same document. 

20. Successor to Company. The Company shall require any successor (whether direct or indirect, by purchase, merger, consolidation or
otherwise) to all or substantially all of the business or assets of the Company expressly to assume and agree to perform this Agreement to the same extent that the Company would be required to perform it if no succession had taken place. Failure of
the Company to obtain an assumption of this Agreement at or prior to the effectiveness of any succession shall be a material breach of this Agreement. 

21. Conditions. Notwithstanding anything to the contrary herein, the effectiveness of this Agreement is conditioned on the
Executive’s receipt of an O-1 visa allowing for work in the United States. This Agreement shall be void ab initio and of no further force or effect if the condition set forth in this Section is not
satisfied. 
 22. Gender Neutral. Wherever used herein, a pronoun in the masculine or feminine gender shall be considered as
including the opposite gender as well unless the context clearly indicates otherwise. 
 [Remainder of Page Intentionally Left Blank.] 

  
 14 

 IN WITNESS WHEREOF, the parties have executed this Agreement effective on the date and year
first above written. 
  

			
	AVROBIO, INC.
		
	By:	 	/s/ Geoff MacKay
	Name: Geoff MacKay
	Title: Chief Executive Officer

  

			
	EXECUTIVE
		
		 	/s/ Birgitte Volck
		 	Birgitte Volck, MD

 Schedule 1 

Approved Activities 
 Board of Directors
of: 
  

	 	•	 	 Ascendis Pharma A/S (Nasdaq ASND) 

 

	 	•	 	 Trial Form Support TFS 

 Exhibit A 

Restrictive Covenants Agreement

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00293-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00293-of-00352.parquet"}]]